Additionally, studies examining the dose-dependent effects of β-Pro7 Ang III over longer treatment periods would provide further insights into its sustained ability to treat IPF and related fibrotic conditions. The gene discussed is AGT; the disease is idiopathic pulmonary fibrosis.